source
- J&J strikes up to $925M deal with Sail Biomedicines, secures option to buy for $2.58BJohnson & Johnson announced a collaboration with Flagship Pioneering’s Sail Biomedicines to develop in vivo CAR‑T therapies for immune‑mediated diseases. The agreement provides up to $925 million i…
- FDA advisory panel backs Replimune's melanoma therapy RP1, raising approval prospectsAdvisors to the U.S. Food and Drug Administration voted 10-3 in favor of Replimune's experimental melanoma treatment, RP1, despite lingering scientific concerns about the data presented. The panel…